This website is not owned by Johnson & Johnson Medical Pty. Ltd, and we do not review or control the content of this website. Products discussed on this website may not be approved for use or may be approved for different indications in your country. Before using any medical device, review all relevant Instructions for Use, Package Inserts or Summary of Product Characteristics. We do not endorse the use or promotion of unapproved products or indications. Any demonstrations of approved medical devices should be considered as information only and are not a surgical training guide.
Optimising Haemostat Use
Surgical bleeding can adversely affect patient outcomes, hospital costs and resources.1–7
Compared to primary methods of haemostasis alone, optimal use of adjunctive haemostats have been associated with improved patient outcomes and reduced use of hospital resources.8–19
Haemostasis Optimisation Program
Haemostasis Optimisation Program (HOP) is designed to improve utilisation of adjunctive haemostats through a systematic approach. It provides guidance on selecting an appropriate adjunctive haemostat for a particular bleeding site and situation.
An Evidence-based Approach to Surgical Bleeding
HOP is based on a large-scale quantitative study on the optimal use of adjunctive haemostats. The study, initiated by Ethicon, involved 11 specialties, 450 surgeons and 7,864 bleeding occasions.16
Your partner in patient care
The Hemostasis Optimisation Program simplifies the identification of the optimal adjunctive haemostat for each bleeding situation by:
Real-world Benefits
HOP demonstrated in a real-world setting that it can help hospitals achieve substantial cost savings by shifting to a more cost-effective use of haemostats — without sacrificing effectiveness or affecting patient outcomes.*16
*Results may vary by specific adjunctive haemostat used. Data based on a US dataset and monetary calculations are in US dollars.
Helping you Succeed
We can help you create an implementation plan that is customised to your facility and clinical teams needs. Resources for your teams to communicate education, training, and trial plans to an extended audience are available. For further information, please click below to contact your Ethicon representative.
References
- Corral M et al. Clinicoecon Outcomes Res. 2015;7:409–21.
- Marietta M et al. Transplant Proc. 2006;38(3):812–4.
- Stokes ME et al. BMC Health Serv Res. 2011;11:135.
- Kahn JM et al. Med Care. 2008;46(12):1226–33.
- Dasta JF et al. Crit Care Med. 2005;33(6):1266–71.
- Toner RW et al. Appl Health Econ Health Policy. 2011;9(1):29–37.
- l-Attar N et al. J Cardiothorac Surg. 2019;14(1):64.
- Notarnicola A et al. Blood Coagul Fibrinolysis. 2012;23(4):278–84
- Dancey AL et al. Plast Reconstr Surg. 2010;125(5):1309–17.
- Pan HW et al. Ophthalmology. 2011;118(6):1049–54.
- Molloy DO et al. J Bone Joint Surg Br. 2007;89(3):306–9.
- Sabatini L et al. J Orthop Traumatol. 2012;13(3):145–51.
- Wang GJ et al. J Bone Joint Surg. 2001;83-A(10):1503–5.
- Randelli F et al. Int J Immunopathol Pharmacol. 2013;26(1):189–97.
- Joseph T et al. Eur J Vasc Endovasc Surg. 2004;27:549–52.
- Ferko N et al. Healthcare Purchasing News. 2017;41(11):34–5.
- Levy J et al. Anesth Analg. 2010;110(2):354–64.
- Liu L et al. PLoS One. 2013;8(5):e64261.
- Massin P et al. Orthop Traumatol Surg Res. 2012;98(2):180–5.
196038-211116